Ongoing federal support for mRNA technology and research could make good on a longstanding presidential promise to cure cancer, according to Jeff Coller, Bloomberg Distinguished Professor of RNA ...
As the U.S. backpedals on its mRNA investment, Mexico is embracing the technology through a new manufacturing pact with ...
Aside from maybe high school biology classes, the first time many people heard of mRNA was during the pandemic because of the vital role MRNA technology played in COVID-19 vaccines. Subscribe to ...
WASHINGTON, DC: Jayanta Bhattacharya, Director of the National Institutes of Health. (Photo by Andrew Harnik/Getty Images) Director of the National Institutes of Health, Jay Bhattacharya, recently ...
The United States is turning its back on what could be the greatest medical advance in a generation — vaccines made with messenger RNA, or mRNA, technology. The U.S. Department of Health and Human ...
Hosted on MSN
How the mRNA technology behind COVID-19 vaccines could ‘turbo-charge’ cancer treatments
The mRNA technology from COVID-19 vaccines may help amplify cancer treatments that use the body’s own immune system to fight cancer, a new study has found. Cancer patients who received an ...
The world could be only a few years away from a cancer vaccine, according to the couple behind the Pfizer/BioNtech COVID-19 vaccine. "We feel that a cure for cancer or to changing cancer patients' ...
Add Yahoo as a preferred source to see more of our stories on Google. Health and Human Services Secretary Robert F. Kennedy Jr. canceled $500 million of funding for research on mRNA vaccine ...
Since the announcements by federal health authorities earlier this year that federal mRNA vaccine funding will be curtailed, a fierce debate has taken place around the future of mRNA-based ...
EDITOR’S NOTE: The views expressed in this commentary are solely those of the writer. CNN is showcasing the work of The Conversation, a collaboration between journalists and academics to provide news ...
A new personalized mRNA melanoma vaccine developed by Moderna and Merck is showing promising results, cutting the risk of cancer recurrence nearly in half for high-risk patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results